wayground logo

Free Printable Worksheets

Font size

S
M
L
XL
Worksheets

SPARTAN QUIZ 2

Total questions: 10

Worksheet time: 5mins

Name
Class
Date
1.

What are the trials that were able to meet primary endpoint?

a)

TRANSFORM-1 and SUSTAIN-1

b)

  TRANSFORM-2 and SUSTAIN-1

c)

   TRANSFORM-1 and SUSTAIN-2

d)

TRANSFORM-2 and SUSTAIN-2

2.

In MADRS, the minimal clinically important difference (MCID) is a score change of between:

a)

1.6 and 1.9 points

b)

1.7 and 2.0 points

c)

1.5 and 1.8 points

d)

1.4 and 1.7 points

3.

How many items are there in the Montgomery-Asberg Depression Rating Scale?

a)

7 items

b)

8 items

c)

10 items

d)

11 items

4.

In the clinical trials, response rate is defined as:

a)

More than or equal to 40% improvement on MADRS from baseline

b)

More than or equal to 50% improvement on MADRS from baseline

c)

More than or equal to 60% improvement on MADRS from baseline

d)

More than or equal to 70% improvement on MADRS from baseline

5.

In general, remission rate is defined as:

a)

MADRS total score of less than or equal to 9

b)

MADRS total score of less than or equal to 11

c)

MADRS total score of less than or equal to 12

d)

MADRS total score of less than or equal to 13

6.

In SUSTAIN-1, relapse is defined as:

a)

MADRS total score of more than or equal to 19 for 2 consecutive assessments

b)

MADRS total score of more than or equal to 22 for 3 consecutive assessments

c)

MADRS total score of more than or equal to 19 for 3 consecutive assessments

d)

MADRS total score of more than or equal to 22 for 2 consecutive assessments

7.

In SUSTAIN-2, patients were recruited by:

a)

Direct-entry patients only

b)

Direct-entry and transferred-entry patients

c)

Transferred-entry patients only

d)

None of the above

8.

In SUSTAIN-2, primary objectives included assessing long-term safety and tolerability by assessing:

a)

Potential effects on cognitive function

b)

Potential treatment-emergent symptoms of cystitis

c)

Potential withdrawal and/or rebound symptoms following cessation of intranasal esketamine treatment

d)

All of the above

9.

Non-responder is defined as:

a)

Less than or equal to 15% improvement in MADRS score

b)

Less than or equal to 20% improvement in MADRS score

c)

Less than or equal to 25% improvement in MADRS score

d)

Less than or equal to 30% improvement in MADRS score

10.

In TRANSFORM-2, the primary endpoint was:

a)

Change in MADRS total score from Day 1 to Day 2

b)

Change in MADRS total score from Day 1 to Day 4

c)

Change in MADRS total score from Day 1 to Day 7

d)

Change in MADRS total score from Day 1 to Day 28